Overview
Carlo Agostini practices in Treviso, Italy. Mr. Agostini is rated as an Elite expert by MediFind in the treatment of Common Variable Immune Deficiency. His top areas of expertise are Common Variable Immune Deficiency, Primary Immunodeficiency (PID), Secondary Immunodeficiency (SID), Sarcoidosis, and Lung Transplant.
His clinical research consists of co-authoring 81 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Common Variable Immune Deficiency.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Common Variable Immune Deficiency
- Advanced
- Primary Immunodeficiency (PID)Mr. Agostini isAdvanced. Learn about Primary Immunodeficiency (PID).
- Secondary Immunodeficiency (SID)Mr. Agostini isAdvanced. Learn about Secondary Immunodeficiency (SID).
- Experienced
- Acute Interstitial PneumoniaMr. Agostini isExperienced. Learn about Acute Interstitial Pneumonia.
- AgranulocytosisMr. Agostini isExperienced. Learn about Agranulocytosis.
- Bartter SyndromeMr. Agostini isExperienced. Learn about Bartter Syndrome.
- CalcinosisMr. Agostini isExperienced. Learn about Calcinosis.
- Cerebral HypoxiaMr. Agostini isExperienced. Learn about Cerebral Hypoxia.
- Chronic B-Cell Leukemia (CBCL)Mr. Agostini isExperienced. Learn about Chronic B-Cell Leukemia (CBCL).